<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33857435</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-2619</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>The Lancet. Respiratory medicine</Title><ISOAbbreviation>Lancet Respir Med</ISOAbbreviation></Journal><ArticleTitle>Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses.</ArticleTitle><Pagination><StartPage>533</StartPage><EndPage>544</EndPage><MedlinePgn>533-544</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2213-2600(21)00125-9</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-2600(21)00125-9</ELocationID><Abstract><AbstractText>Cough is one of the most common presenting symptoms of COVID-19, along with fever and loss of taste and smell. Cough can persist for weeks or months after SARS-CoV-2 infection, often accompanied by chronic fatigue, cognitive impairment, dyspnoea, or pain-a collection of long-term effects referred to as the post-COVID syndrome or long COVID. We hypothesise that the pathways of neurotropism, neuroinflammation, and neuroimmunomodulation through the vagal sensory nerves, which are implicated in SARS-CoV-2 infection, lead to a cough hypersensitivity state. The post-COVID syndrome might also result from neuroinflammatory events in the brain. We highlight gaps in understanding of the mechanisms of acute and chronic COVID-19-associated cough and post-COVID syndrome, consider potential ways to reduce the effect of COVID-19 by controlling cough, and suggest future directions for research and clinical practice. Although neuromodulators such as gabapentin or opioids might be considered for acute and chronic COVID-19 cough, we discuss the possible mechanisms of COVID-19-associated cough and the promise of new anti-inflammatories or neuromodulators that might successfully target both the cough of COVID-19 and the post-COVID syndrome.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Woo-Jung</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>Christopher K M</ForeName><Initials>CKM</Initials><AffiliationInfo><Affiliation>Royal Free Hampstead NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hull</LastName><ForeName>James H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Royal Brompton and Harefield NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birring</LastName><ForeName>Surinder S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Centre for Human &amp; Applied Physiological Sciences, School of Basic &amp; Medical Biosciences, Faculty of Life Sciences &amp; Medicine, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGarvey</LastName><ForeName>Lorcan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzone</LastName><ForeName>Stuart B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Physiology, University of Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Kian Fan</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Royal Brompton and Harefield NHS Trust, London, UK; Experimental Studies Unit, National Heart &amp; Lung Institute, Imperial College London, UK. Electronic address: f.chung@imperial.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Respir Med</MedlineTA><NlmUniqueID>101605555</NlmUniqueID><ISSNLinking>2213-2600</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003371" MajorTopicYN="N">Cough</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015213" MajorTopicYN="Y">Neuroimmunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests KFC has received honoraria for participating in advisory board meetings for GlaxoSmithKline, AstraZeneca, Novartis, Merck, Boehringer Ingelheim, Nocion, Shionogi, Roche, and TEVA Pharmaceutical regarding treatments for asthma and chronic obstructive pulmonary disease; he has recieved honoraria for participating on the scientific advisory board of the Clean Breathing Institute, supported by GlaxoSmithKline Health Care Consumer Products; and he has been remunerated for speaking engagements by AstraZeneca, Novartis, and Merck. SBM reports grants from Merck and personal fees from Merck and NeRRe Therapeutics. SSB reports personal fees from Nocion, Merck, Nerre, Bayer, Bellus, and Shionogi; and grants from Merck, all outside the submitted work. LM reports personal fees from GlaxoSmithKline, Merck, Shionogi, Bayer, Bellus Health, Nocion, Chiesi, and Applied Clinical Intelligence; and grants from Merck and Chesi, all outside the submitted work. JHH has received grant funding and advisory fees from MSD pharmaceuticals and is a member of the advisory board for Bellus health. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33857435</ArticleId><ArticleId IdType="pmc">PMC8041436</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(21)00125-9</ArticleId><ArticleId IdType="pii">S2213-2600(21)00125-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhand R, Li J. Coughs and sneezes: their role in transmission of respiratory viral infections, including SARS-CoV-2. Am J Respir Crit Care Med. 2020;202:651&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462404</ArticleId><ArticleId IdType="pubmed">32543913</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulme K, Dogan S, Parker SM, Deary V. &#x2018;Chronic cough, cause unknown&#x2019;: A qualitative study of patient perspectives of chronic refractory cough. J Health Psychol. 2019;24:707&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">28810370</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 2020;26:1037&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7751267</ArticleId><ArticleId IdType="pubmed">32393804</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant MC, Geoghegan L, Arbyn M, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7310678</ArticleId><ArticleId IdType="pubmed">32574165</ArticleId></ArticleIdList></Reference><Reference><Citation>Canning BJ, Chang AB, Bolser DC, et al. Anatomy and neurophysiology of cough: CHEST Guideline and Expert Panel report. Chest. 2014;146:1633&#x2013;1648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4251621</ArticleId><ArticleId IdType="pubmed">25188530</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81:e4&#x2013;e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021;93:1013&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J. 2020;56</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7530908</ArticleId><ArticleId IdType="pubmed">33008936</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6:00542&#x2013;02020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, et al. &#x2018;Long-COVID&#x2019;: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2020;76:396&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, Gemelli Against C-P-ACSG Persistent symptoms in patients after Acute COVID-19. JAMA. 2020;324:603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng D, Calderwood C, Skyllberg E, Ainley A. Clinical characteristics and outcomes of adult patients admitted with COVID-19 in East London: a retrospective cohort analysis. BMJ Open Respir Res. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7976675</ArticleId><ArticleId IdType="pubmed">33731329</ArticleId></ArticleIdList></Reference><Reference><Citation>Moradian ST, Parandeh A, Khalili R, Karimi L. Delayed symptoms in patients recovered from COVID-19. Iran J Public Health. 2020;49:2120&#x2013;2127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7917497</ArticleId><ArticleId IdType="pubmed">33708732</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Cruz RF, Waller MD, Perrin F, et al. Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. ERJ Open Res. 2021;7:00655&#x2013;02020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7585700</ArticleId><ArticleId IdType="pubmed">33575312</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2020;11:M20&#x2013;5661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7707210</ArticleId><ArticleId IdType="pubmed">33175566</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76:399&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnweber T, Sahanic S, Pizzini A, et al. Cardiopulmonary recovery after COVID-19 &#x2014; an observational prospective multi-center trial. Eur Respir J. 2020 doi: 10.1183/13993003.03481-2020. published online Dec 10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03481-2020</ArticleId><ArticleId IdType="pmc">PMC7736754</ArticleId><ArticleId IdType="pubmed">33303539</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27:89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510771</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao YM, Shang YM, Song WB, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>Valiente-De Santis L, Perez-Camacho I, Sobrino B, et al. Clinical and immunoserological status 12 weeks after infection with COVID-19: prospective observational study. medRxiv. 2020 doi: 10.1101/2020.10.06.20206060. published online Dec 10. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.06.20206060</ArticleId></ArticleIdList></Reference><Reference><Citation>Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Persistent symptoms 1&#xb7;5&#x2013;6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax. 2020 doi: 10.1136/thoraxjnl-2020-216377. published online December 3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216377</ArticleId><ArticleId IdType="pmc">PMC7716295</ArticleId><ArticleId IdType="pubmed">33273028</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MS, Kristiansen MF, Hanusson KD, et al. Long COVID in the Faroe Islands-a longitudinal study among non-hospitalized patients. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa1792. published online Nov 30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1792</ArticleId><ArticleId IdType="pmc">PMC7799340</ArticleId><ArticleId IdType="pubmed">33252665</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein H, Asseo K, Karni N, et al.  Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients. Clin Microbiol Infect. 2021 https://doi:10.1016/j.cmi.2021.02.008 published online Feb 16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.02.008</ArticleId><ArticleId IdType="pmc">PMC7884919</ArticleId><ArticleId IdType="pubmed">33607252</ArticleId></ArticleIdList></Reference><Reference><Citation>Guler SA, Ebner L, Beigelman C, et al. Pulmonary function and radiological features four months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J. 2021;57</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8082329</ArticleId><ArticleId IdType="pubmed">33419891</ArticleId></ArticleIdList></Reference><Reference><Citation>Assaf G, Davis H, McCorkell L, Wei H, O'Neill B, Akrami A.  The COVID-19 Body Politic Slack Group; London, UK: 2020. What does COVID-19 recovery actually look like? An analysis of the prolonged COVID-19 symptoms survey by patient-led research team.https://patientresearchcovid19.com/research/report-1/</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. medRxiv. 2020 doi: 10.1101/2020.10.19.20214494. published online Dec 19. (preprint).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.19.20214494</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics COVID-19 Infection Survey  Coronavirus (COVID-19) https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases</Citation></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojha V, Mani A, Pandey NN, Sharma S, Kumar S. CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients. Eur Radiol. 2020;30:6129&#x2013;6138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261039</ArticleId><ArticleId IdType="pubmed">32474632</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones RM, Hilldrup S, Hope-Gill BD, Eccles R, Harrison NK. Mechanical induction of cough in idiopathic pulmonary fibrosis. Cough. 2011;7:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094358</ArticleId><ArticleId IdType="pubmed">21477349</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung KF, McGarvey L, Mazzone SB. Chronic cough as a neuropathic disorder. Lancet Respir Med. 2013;1:414&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">24429206</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA. 2020;117:11727&#x2013;11734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260975</ArticleId><ArticleId IdType="pubmed">32376634</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzone SB, Tian L, Moe AAK, Trewella MW, Ritchie ME, McGovern AE. Transcriptional profiling of individual airway projecting vagal sensory neurons. Mol Neurobiol. 2020;57:949&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">31630330</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies J, Randeva HS, Chatha K, et al. Neuropilin1 as a new potential SARSCoV2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID19. Mol Med Rep. 2020;22:4221&#x2013;4226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7533503</ArticleId><ArticleId IdType="pubmed">33000221</ArticleId></ArticleIdList></Reference><Reference><Citation>Brann DH, Tsukahara T, Weinreb C, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. 2020;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10715684</ArticleId><ArticleId IdType="pubmed">32937591</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Shen W, Rowan NR, et al. Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication. Eur Respir J. 2020;56</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7439429</ArticleId><ArticleId IdType="pubmed">32817004</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiers S, Ray PR, Wangzhou A, et al. ACE2 and SCARF expression in human dorsal root ganglion nociceptors: implications for SARS-CoV-2 virus neurological effects. Pain. 2020;161:2494&#x2013;2501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7572821</ArticleId><ArticleId IdType="pubmed">32826754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupari J, H&#xe4;ring M, Agirre E, Castelo-Branco G, Ernfors P. An atlas of vagal sensory neurons and their molecular specialization. Cell Rep. 2019;27:2508&#x2013;2523.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6533201</ArticleId><ArticleId IdType="pubmed">31116992</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021;24:168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021;218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Driessen AK, Farrell MJ, Mazzone SB, McGovern AE. Multiple neural circuits mediating airway sensations: recent advances in the neurobiology of the urge-to-cough. Respir Physiol Neurobiol. 2016;226:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">26455780</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhea EM, Logsdon AF, Hansen KM, et al. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci. 2020;24:368&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8793077</ArticleId><ArticleId IdType="pubmed">33328624</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosato PC, Leib DA. Neuronal interferon signaling is required for protection against herpes simplex virus replication and pathogenesis. PLoS Pathog. 2015;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4495997</ArticleId><ArticleId IdType="pubmed">26153886</ArticleId></ArticleIdList></Reference><Reference><Citation>Undem BJ, Zaccone E, McGarvey L, Mazzone SB. Neural dysfunction following respiratory viral infection as a cause of chronic cough hypersensitivity. Pulm Pharmacol Ther. 2015;33:52&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4532602</ArticleId><ArticleId IdType="pubmed">26141017</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620&#x2013;2629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Verzele NAJ, Chua BY, Law CW, et al. The impact of influenza pulmonary infection and inflammation on vagal bronchopulmonary sensory neurons. FASEB J. 2021;35</Citation><ArticleIdList><ArticleId IdType="pubmed">33660333</ArticleId></ArticleIdList></Reference><Reference><Citation>Driessen AK, Devlin AC, Lundy FT, et al. Perspectives on neuroinflammation contributing to chronic cough. Eur Respir J. 2020;56</Citation><ArticleIdList><ArticleId IdType="pubmed">32646920</ArticleId></ArticleIdList></Reference><Reference><Citation>Park CK, Xu ZZ, Berta T, et al. Extracellular microRNAs activate nociceptor neurons to elicit pain via TLR7 and TRPA1. Neuron. 2014;82:47&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3982230</ArticleId><ArticleId IdType="pubmed">24698267</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, von Hehn CA, Woolf CJ. Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. Nat Neurosci. 2012;15:1063&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3520068</ArticleId><ArticleId IdType="pubmed">22837035</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Z, Zhou W, Sun J, Li C, Zhong B, Lai K. IFN-&#x3b3; enhances the cough reflex sensitivity via calcium influx in vagal sensory neurons. Am J Respir Crit Care Med. 2018;198:868&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">29672123</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil MJ, Ru F, Sun H, et al. Acute activation of bronchopulmonary vagal nociceptors by type I interferons. J Physiol. 2020;598:5541&#x2013;5554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7772956</ArticleId><ArticleId IdType="pubmed">32924209</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahama A, Ramachandran R, Cisternas AF, Ji H. The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis: a review. Med Drug Discov. 2020;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147194</ArticleId><ArticleId IdType="pubmed">32292906</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray PR, Wangzhou A, Ghneim N, et al. A pharmacological interactome between COVID-19 patient samples and human sensory neurons reveals potential drivers of neurogenic pulmonary dysfunction. Brain Behav Immun. 2020;89:559&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7263237</ArticleId><ArticleId IdType="pubmed">32497778</ArticleId></ArticleIdList></Reference><Reference><Citation>Ydens E, Lornet G, Smits V, Goethals S, Timmerman V, Janssens S. The neuroinflammatory role of Schwann cells in disease. Neurobiol Dis. 2013;55:95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">23523637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ntogwa M, Imai S, Hiraiwa R, et al. Schwann cell-derived CXCL1 contributes to human immunodeficiency virus type 1 gp120-induced neuropathic pain by modulating macrophage infiltration in mice. Brain Behav Immun. 2020;88:325&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">32229220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AP, Undem BJ. The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Front Cell Neurosci. 2013;7:267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867694</ArticleId><ArticleId IdType="pubmed">24391544</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdullah H, Heaney LG, Cosby SL, McGarvey LP. Rhinovirus upregulates transient receptor potential channels in a human neuronal cell line: implications for respiratory virus-induced cough reflex sensitivity. Thorax. 2014;69:46&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">24002057</ArticleId></ArticleIdList></Reference><Reference><Citation>Dicpinigaitis PV, Bhat R, Rhoton WA, Tibb AS, Negassa A. Effect of viral upper respiratory tract infection on the urge-to-cough sensation. Respir Med. 2011;105:615&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">21185164</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson SK, Morice AH, Sadofsky LR. Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production. ERJ Open Res. 2020;6:00159&#x2013;02020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7569158</ArticleId><ArticleId IdType="pubmed">33123553</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JA, Kitt MM, Morice AH, et al. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med. 2020;8:775&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pubmed">32109425</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr MJ, Hunter DD, Jacoby DB, Undem BJ. Expression of tachykinins in nonnociceptive vagal afferent neurons during respiratory viral infection in guinea pigs. Am J Respir Crit Care Med. 2002;165:1071&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pubmed">11956047</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaccone EJ, Lieu T, Muroi Y, et al. Parainfluenza 3-induced cough hypersensitivity in the guinea pig airways. PLoS One. 2016;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4877001</ArticleId><ArticleId IdType="pubmed">27213574</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung KF, McGarvey L, Mazzone SB. Chronic cough as a neuropathic disorder. Lancet Respir Med. 2013;1:414&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">24429206</ArticleId></ArticleIdList></Reference><Reference><Citation>Driessen AK, McGovern AE, Narula M, et al. Central mechanisms of airway sensation and cough hypersensitivity. Pulm Pharmacol Ther. 2017;47:9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">28137663</ArticleId></ArticleIdList></Reference><Reference><Citation>Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82:7264&#x2013;7275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493326</ArticleId><ArticleId IdType="pubmed">18495771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed MU, Hanif M, Ali MJ, et al. Neurological manifestations of COVID-19 (SARS-CoV-2): a review. Front Neurol. 2020;11:518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7257377</ArticleId><ArticleId IdType="pubmed">32574248</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracely RH, Undem BJ, Banzett RB. Cough, pain and dyspnoea: similarities and differences. Pulm Pharmacol Ther. 2007;20:433&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213909</ArticleId><ArticleId IdType="pubmed">17336558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando A, Smallwood D, McMahon M, Irving L, Mazzone SB, Farrell MJ. Neural correlates of cough hypersensitivity in humans: evidence for central sensitisation and dysfunctional inhibitory control. Thorax. 2016;71:323&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">26860344</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121:953&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">7978722</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes Rivera M, Mastronardi C, Silva-Aldana CT, Arcos-Burgos M, Lidbury BA. Myalgic encephalomyelitis/chronic fatigue syndrome: a comprehensive review. Diagnostics. 2019;9:73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6787585</ArticleId><ArticleId IdType="pubmed">31394725</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiffer C, Costes N, Herv&#xe9; P, Garcia-Larrea L. Relief of dyspnea involves a characteristic brain activation and a specific quality of sensation. Am J Respir Crit Care Med. 2008;177:440&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">18048808</ArticleId></ArticleIdList></Reference><Reference><Citation>Katal S, Gholamrezanezhad A. Neuroimaging findings in COVID-19: a narrative review. Neurosci Lett. 2021;742</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7686796</ArticleId><ArticleId IdType="pubmed">33248161</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Campion J, Dudouet P, et al. 18 F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021 doi: 10.1007/s00259-021-05215-4. published online Jan 26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pmc">PMC7837643</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson P, Wang G, McGarvey L, et al. Treatment of Unexplained Chronic Cough: CHEST guideline and expert panel report. Chest. 2016;149:27&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5831652</ArticleId><ArticleId IdType="pubmed">26426314</ArticleId></ArticleIdList></Reference><Reference><Citation>Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942543</ArticleId><ArticleId IdType="pubmed">31515408</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzone SB, McGarvey L. Mechanisms and rationale for targeted therapies in refractory and unexplained chronic cough. Clin Pharmacol Ther. 2020 doi: 10.1002/cpt.2003. published online Aug 4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2003</ArticleId><ArticleId IdType="pmc">PMC7983941</ArticleId><ArticleId IdType="pubmed">32748976</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder K, Fahey T. Systematic review of randomised controlled trials of over the counter cough medicines for acute cough in adults. BMJ. 2002;324:329&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC65295</ArticleId><ArticleId IdType="pubmed">11834560</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC, Cheng AC, Chang AB. Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database Syst Rev. 2014;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11023600</ArticleId><ArticleId IdType="pubmed">24615334</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence in collaboration with NHS England and NHS Improvement Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines. BMJ. 2020;369</Citation><ArticleIdList><ArticleId IdType="pubmed">33497151</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WJ, Chung KF. Pharmacotherapeutic options for chronic refractory cough. Expert Opin Pharmacother. 2020;21:1345&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pubmed">32301356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hay AD, Little P, Harnden A, et al. Effect of oral prednisolone on symptom duration and severity in nonasthmatic adults with acute lower respiratory tract infection: a randomized clinical trial. JAMA. 2017;318:721&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5817483</ArticleId><ArticleId IdType="pubmed">28829884</ArticleId></ArticleIdList></Reference><Reference><Citation>Group RC. Dexamethasone in hospitalized patients with Covid-19&#x2014;preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2021436. published online Feb 25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489411</ArticleId><ArticleId IdType="pubmed">32876695</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19&#x2014;preliminary report. N Engl J Med. 2020;383:1813&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pubmed">32649078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:1583&#x2013;1589.</Citation><ArticleIdList><ArticleId IdType="pubmed">22951084</ArticleId></ArticleIdList></Reference><Reference><Citation>Vertigan AE, Kapela SL, Ryan NM, Birring SS, McElduff P, Gibson PG. Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomized controlled trial. Chest. 2016;149:639&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">26447687</ArticleId></ArticleIdList></Reference><Reference><Citation>Dicpinigaitis PV, Spinner L, Santhyadka G, Negassa A. Effect of tiotropium on cough reflex sensitivity in acute viral cough. Lung. 2008;186:369&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">18787899</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain Mitchell SA, Garrod R, Clark L, et al. Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax. 2017;72:129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">27682331</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith J, Allman D, Badri H, et al. The neurokinin-1 receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 pilot study (VOLCANO-1) Chest. 2020;157:111&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">31421110</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JA, Harle A, Dockry R, et al. Aprepitant for cough in lung cancer: a randomised placebo-controlled trial and mechanistic insights. Am J Respir Crit Care Med. 2020 doi: 10.1164/rccm.202006-2359OC. published online Sept 23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202006-2359OC</ArticleId><ArticleId IdType="pmc">PMC7958516</ArticleId><ArticleId IdType="pubmed">32966755</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid S, Murdoch R, Newlands A, et al. Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial. J Allergy Clin Immunol. 2014;134:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24666696</ArticleId></ArticleIdList></Reference><Reference><Citation>Belvisi MG, Birrell MA, Wortley MA, et al. XEN-D0501, a novel transient receptor potential vanilloid 1 antagonist, does not reduce cough in patients with refractory cough. Am J Respir Crit Care Med. 2017;196:1255&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pubmed">28650204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>